Erectile dysfunction and diabetes: A melting pot of circumstances and treatments

G Defeudis, R Mazzilli, M Tenuta… - Diabetes/metabolism …, 2022 - Wiley Online Library
Diabetes mellitus (DM), a chronic metabolic disease characterised by elevated levels of
blood glucose, is among the most common chronic diseases. The incidence and prevalence …

Beyond erectile dysfunction: cGMP-specific phosphodiesterase 5 inhibitors for other clinical disorders

A Samidurai, L Xi, A Das… - Annual review of …, 2023 - annualreviews.org
Cyclic guanosine monophosphate (cGMP), an important intracellular second messenger,
mediates cellular functional responses in all vital organs. Phosphodiesterase 5 (PDE5) is …

cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action

SH Francis, JL Busch, JD Corbin - Pharmacological reviews, 2010 - ASPET
To date, studies suggest that biological signaling by nitric oxide (NO) is primarily mediated
by cGMP, which is synthesized by NO-activated guanylyl cyclases and broken down by …

Mammalian cyclic nucleotide phosphodiesterases: molecular mechanisms and physiological functions

SH Francis, MA Blount, JD Corbin - Physiological reviews, 2011 - journals.physiology.org
The superfamily of cyclic nucleotide (cN) phosphodiesterases (PDEs) is comprised of 11
families of enzymes. PDEs break down cAMP and/or cGMP and are major determinants of …

Cyclic GMP signaling in cardiovascular pathophysiology and therapeutics

EJ Tsai, DA Kass - Pharmacology & therapeutics, 2009 - Elsevier
Cyclic guanosine 3', 5'-monophosphate (cGMP) mediates a wide spectrum of physiologic
processes in multiple cell types within the cardiovascular system. Dysfunctional signaling at …

Cyclic nucleotide phosphodiesterases as therapeutic targets in cardiac hypertrophy and heart failure

R Kamel, J Leroy, G Vandecasteele… - Nature Reviews …, 2023 - nature.com
Cyclic nucleotide phosphodiesterases (PDEs) modulate the neurohormonal regulation of
cardiac function by degrading cAMP and cGMP. In cardiomyocytes, multiple PDE isozymes …

PDE5 inhibitors as therapeutics for heart disease, diabetes and cancer

A Das, D Durrant, FN Salloum, L Xi… - Pharmacology & …, 2015 - Elsevier
Abstract The phosphodiesterase 5 (PDE5) inhibitors, including sildenafil (Viagra™),
vardenafil (Levitra™), and tadalafil (Cialis™) have been developed for treatment of erectile …

Diagnosis, assessment, and treatment of non-pulmonary arterial hypertension pulmonary hypertension

MM Hoeper, JA Barberà, RN Channick… - Journal of the American …, 2009 - jacc.org
The 4th World Symposium on Pulmonary Hypertension was the first international meeting to
focus not only on pulmonary arterial hypertension (PAH) but also on the so-called non-PAH …

Anakinra, a recombinant human interleukin-1 receptor antagonist, inhibits apoptosis in experimental acute myocardial infarction

A Abbate, FN Salloum, E Vecile, A Das, NN Hoke… - Circulation, 2008 - Am Heart Assoc
Background—Experimental interleukin-1 receptor antagonist gene overexpression has
shown that interleukin-1 receptor antagonist is cardioprotective during global cardiac …

Mitochondrial-targeted Signal transducer and activator of transcription 3 (STAT3) protects against ischemia-induced changes in the electron transport chain and the …

K Szczepanek, Q Chen, M Derecka, FN Salloum… - Journal of Biological …, 2011 - ASBMB
Expression of the STAT3 transcription factor in the heart is cardioprotective and decreases
the levels of reactive oxygen species. Recent studies indicate that a pool of STAT3 resides …